Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in IgA Nephropathy (Double-Blind, Randomized, Placebo-Controlled Phase IIa Study)
jRCT2071210119Phase 2Completed
- Sponsor
- Human Immunology Biosciences
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of felzartamab in IgA nephropathy (IgAN) (5 arms), sponsored by Human Immunology Biosciences. Primary endpoint: Relative change in UPCR in 24-hour urine at 9 months. Started Jan 2022; status: completed.
02
Drugs
felzartamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2071210119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210119.